Livingstone polled four industry experts to explore the key factors driving the medtech M&A boom.
Livingstone curated a panel of CEOs, medical device manufacturers (OEMs), and private equity investors to discuss key drivers of the medtech M&A boom. We explored why medtech assets are trading at premium prices, asked how consolidation in the global medtech industry is impacting companies throughout the supply chain, and discussed what the future holds for medtech industry participants.
Karl Freimuth, partner and co-head of the US industrials practice at Livingstone moderated the discussion. Panelists included:
We’ve pulled together their thoughts on the topic. Find the collection here, otherwise click-through the discussion topics below.
To access a pdf copy of the report, please click the link below.
Share on: